scispacy								
file_path	sentence	section entities	labels	position_start	position_end	abbreviations abbreviations_longform	abbreviation_start	t abbreviation_end
72 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/1_front/1_article-meta/17_abstract.xn	Meta-analysis favored EAHM monotherapy on Psoriasis Area Severity Index (PASI) 70 (RR: 1.2845; 95% CI: 1.906 to 1.3858, p < 0.0001), PASI 60 (RR: 1.1823; 95% CI: 1.1134 to 1.2769, p < 0.0001), continuous PASI score	ABS Psoriasis	DISEASE		42 5	1 PASI, PASI, PASI Psoriasis Area Severity Index, Psoriasis Area Severity Index, Psoriasis Area Severity Index	. 56, 33, 10	57, 34, 11
130 /Users/emanuelfarruda/venv/phytomed100/PMC8749048/sections/1_front/1_article-meta/14_abstract.xm	d Overall, most of the natural products reported in this review can reduce and suppress inflammatory markers, like tumor necrosis factor-alpha (INF-o), scavenge reactive oxygen species (ROS), induce cancer cell death throug	ABS tumor necrosis, oxygen, cancer cell death, infections	DISEASE, CHEMICAL, DISEASE, DISEASE	113, 168, 197, 274	127, 174, 214, 284	ROS reactive oxygen species	31	1 32
149 /Users/emanuelfarruda/venv/phytomed100/PMC7703918/sections/0_front/1_article-meta/22_abstract.xm	1 Clinical skin severity was assessed with the psoriasis area index (PASI), whilst ELISA detected the expression of TNF-o, IL-17A, and IL-22.	ABS psoriasis	DISEASE		45 5	4 PASI psoriasis area index	11	1 12
2409 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/2_body/4_5_conclusions/1_p.xml	Meta-analysis showed that EAHM had superior effects compared to the control group in PASI 70, PASI 60, continuous PASI score, IL-17, TNF-o, and DLQI of psoriasis patients.	CON psoriasis	DISEASE		152 16	1		
3855 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/2_body/3_4_discussion/1_4.1_sumn	a At the same time, EAHM showed a superior or similar level of an effect to CM on the inflammatory findings of psoriasis in indicators such as IL-17, IL-23, and TNF-o, and also showed positive results on the quality of life in ps	DIS CM, psoriasis, psoriasis	DISEASE, DISEASE, DISEASE	74, 109, 225	76, 118, 234			
3926 /Users/emanuelfarruda/venv/phytomed100/PMC7703918/sections/1 bodv/3 4. discussion/1 p.xml	Groups that have been treated with Dysidea avara methanolic extracts are most active in reducing symptoms of induced osoriasis by decreasing amounts of IL-22. IL-17A. TNF-g. and decreasing neutrophils' infiltration into	DIS psoriasis, psoriasis	DISEASE, DISEASE	119.259	128. 268			
4062 /Users/emanuelfarruda/venv/phytomed100/PMC9605917/sections/2_body/2_results_and_discussions/3_	p/The vascular endothelial growth factor (VEGP), tumor necrosis factor (TNF-a), IL5, IL9, IL12P 70, monocyte chemotactic protein-1 (MCP-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) were significantly	DIS tumor, necrosis	DISEASE, DISEASE	47, 53	52, 61	VEGF, factor, factor vascular endothelial growth factor, factor (TNF-a, factor (TNF-a, factor (TNF-a, monocyte	c 6, 4, 11, 33, 27, 35	7, 5, 12, 34, 28, 36
4066 /Users/emanuelfarruda/venv/phytomed100/PMC9605917/sections/2 body/2 results and discussions/3	o TVF-q was a cytokine produced naturally by macrophages in response to bacterial infection (Liu et al., 2021b).	DIS bacterial infection	DISEASE		70 8	3		
4860 /Users/emanuelfarruda/venv/phytomed100/PMC8072377/sections/1 bodv/4 discussion/2 p.xml	HSP was also reported to possess anti-inflammatory effects via downreputation of pro-inflammatory cytokines (including TNF-a, IL-6, and IL-18) and NF-xB signaling concomitant with activation of Nrf2 in various in vitro and	DIS HSP. Li	DISEASE, CHEMICAL	0.267	3. 269			-
6712 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/4_floats-	Figure 5 (A) Forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the trials that compared FAHM with CM for II-17 (B) forest plot of the tria	FIG CM CM CM CM	DISEASE DISEASE DISEASE	65 135 205 275	67, 137, 207, 277			
7166 /Lisers/emanuelfarruda/venv/ohvtomed100/PMC9118284/sections/2_body/0_introduction/34_fig.xml	Bicalin activated the TNFR-associated death domain (TRADD) through the extrinsic pathway	FIG Baicalein death	CHEMICAL DISEASE	0.40	9.45	TBADD TNEB-associated death domain	7	7 8
7200 /Lisers/emanuelfarruda/venv/obvtomed100/PMC8579746/sections/2 body/2 review/1 strategies for bu	TGE-a transforming growth factor alpha FGE fibrobiat growth factor. PDGE platelet-derived growth factor. VEGE vascular endothelial growth factor. III-8. interleukin 8. TNF-n tumor percessis factor alpha	FIG tumor pecrosis	DISEASE		185 19	a a a a a a a a a a a a a a a a a a a		-
7405 // lsers/amanuelfaru/a/wenv/obvtomed100/PMC9559187/sections/2_bodv/0_introduction/6_pathogenes	g und Turners associated herebet to the process of the second sec	FIG Illorative colitis tumour necrosis Prostomatitis	DISEASE DISEASE DISEASE	4 162 191	22 177 204			-
882 // Jeses/emanuelfarruda/venv/phytomed100/PMC9090317/sections/2_body/0_introduction/3_p.yml	In other workers SM inhibites FLAP stimulations response to approximate to approximate to get an intervention of the state	INT Tumor necrosis	DISEASE	4, 102, 101	61 7	5		-
912 // Jeans/emanuelianuda/venv/phytomed100/PMC9119294/centians/2_body/0_introduction/3_p.xml	In other works, one minutes we was simulation in response to their resolutions factor and remove and the second of the resolution of collarge and factor of 100 and 50 mode/of factor used classificantly reduced the second black and factor and factor of the resolution factor of the second black and factor of the resolution factor of the second black and factor of the resolution factor of the second black and factor of the second bla	INT urstaral obstruction fibraria baicalain		14 60 70	24 77 99			-
0155 / Learn (american data verily phytomed 100/14/2011/2004/sections/2_00dy/o_introduction/15_0.xml	In uniateral determinants obstruction (poly) induced mile models of an induced mile models, backward and an induced mile accumulation of colleger and motoricum models spin	INT Deselais daeth		0.40	0.45	TRADD THE excepted doubt downin	-	7 0
9136 /Users/emanuellandua/veniv/phytomed100/PMC9118264/sections/2_00dy/0_introduction/34_ing.Xnii	Backetin duvided up HYP-resolution deal out of the Arthree Marketin and APA and Arthree Arthre	INT beidelin, dealth		10,40	9,40	FRADD INFR-associated death domain	10.01	14.00
10 / Osers/emailuenaridua/ver/vphytomed/tou/PMC9118264/sections/2_00dy/o_introduction/9_p.xmi	in addition, bacani decleased the elevated tere of the raty adds (Fry, NF-4, and serial conservor and ogni similation) to adeily COA-catoxyate and AWF-additived potent kinese (AWF-K).	INT balcalin, PA, cholesterol, adelyi COA-carboxylate	OHEMICAL, CHEMICAL, CHEMICAL	13, 72, 93, 130	21,75,100,152	PPA, AMPK Internativation protein kinase		14, 32
9181 /Users/emanueitarruda/venv/pnytomed100/PMC9118284/sections/2_body/0_introduction/13_p.xml	Prevously, it has been shown that bacalein (100 mg/kg, 1V) allevated liver injury in mice through suppression or I+N-Y and INF-a (57).	INI balcalein, iver injury	CHEMICAL, DISEASE	35, 72	44,84			
9184 /Users/emanueltarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/13_p.xml	Bacalen (80 mg/kg/d, orally) for 4 d significantly ameliorated CX 4 -induced acute liver injury in mice through suppression of inflammatory cytokines IL-6 and IN+-a (59).	INI Baicalein, CCI, acute liver injury	CHEMICAL, CHEMICAL, DISEASE	0, 65, 80	9, 68, 98			
9185 /Users/emanuelfarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/13_p.xml	In another animal model, application of baicalin at a dose of 70 mg/kg/d (IP) for 56 days significantly reduced liver index, collagen deposition area, AST, ALT, IL-6, and TNF-0.	INT baicalin	CHEMICAL		40 4	3		
9196 /Users/emanuelfarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/11_p.xml	Baicalin administration (20 mg/kg, IV) markedly restored vascular function through suppression of the NF-kB pathway and plasma superoxide anions, INOS, NO, and TNF-a by improving blood pressure in LPS-induced septic	INT Baicalin, superoxide anions, NO	CHEMICAL, CHEMICAL, CHEMICAL	0, 127, 152	8, 144, 154			
9240 /Users/emanuelfarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/7_p.xml	In vitro results revealed that baicalin (dose of 20 mM for 24 hr) inhibited IL-17-induced inflammatory cascade, blocked lymphocytes' attachment to synovial cells, and decreased the expression of IL-6, TNF-a, intercellular ad	INT baicalin	CHEMICAL		32 4	D ICAM-1, VCAM-1 intercellular adhesion molecule-1, vascular cell adhesion molecule-1	42, 51	43, 52
9245 /Users/emanuelfarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/7_p.xml	In in vitro experiments, baicalin modulated M1 macrophage polarization in LPS-stimulated murine macrophages and reduced the expression of IL-23, IRF5, and TNF-a protein expressions (38).	INT baicalin	CHEMICAL		27 3	5		
1032 /Users/emanuelfarruda/venv/phytomed100/PMC9605917/sections/1_front/1_article-meta/19_kwd-group.	xr Abbreviations ACHE, Acetylcholinesterase ALOX5, Polyunsaturated fatty acid 5-lipoxygenase CE, Collision energy COMT, Catechol O-methyltransferase CRS, Cytokine storm COVID-19, The novel coronavirus pneumonia DF	KEY fatty acid 5-lipoxygenase CE, Catechol, coronavirus pneumonia DP, Kynurenine, Fluoride, Turr	no DISEASE, CHEMICAL, DISEASE, CHEMICAL, CHEMICAL, DISEASE,	CHI 64, 117, 186, 401, 591, 813,	845 92, 125, 210, 411, 599, 827, 902			
1209 /Users/emanuelfarruda/venv/phytomed100/PMC7703918/sections/1_body/2_3_results/3_3.3effect_of_	m Interestingly, medium and high doses in G3–G4, with comparatively low levels of IL-22 and TNF-o, showed stronger anti-psoriasis-like symptoms.	RES IL-22	CHEMICAL		80 8	5		
1210 /Users/emanuelfarruda/venv/phytomed100/PMC7703918/sections/1_body/2_3results/3_3.3effect_of_	m Results indicate that, The level of TNF-a protein expression in skin of G6 (IMQ group) was significantly higher than the G2-G5.	RES IMQ	CHEMICAL		76 7	3		
1226 /Users/emanuelfarruda/venv/phytomed100/PMC9605917/sections/2_body/2_results_and_discussions/3_	p (The vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-a), IL5, IL9, IL12P 70, monocyte chemotactic protein-1 (MCP-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) were significantly	RES tumor, necrosis	DISEASE, DISEASE	47, 53	52, 61	VEGF, factor, factor vascular endothelial growth factor, factor (TNF-a, factor (TNF-a, factor (TNF-a, monocyte	ه 6, 4, 11, 33, 27, 35	7, 5, 12, 34, 28, 36
1226 /Users/emanuelfarruda/venv/phytomed100/PMC9605917/sections/2_body/2_results_and_discussions/3_	p TNF-a was a cytokine produced naturally by macrophages in response to bacterial infection (Liu et al., 2021b).	RES bacterial infection	DISEASE		70 8	3		
1373 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/17_table-wrap/3_table	xl First Author (Year) EAHM (Latin Name) Target Cell Line or Animal Model Possible Active Ingredients Possible Mechanisms Sui (2013) 109 Rehmanniae Radix Recens -UVB ray treated mice Radix Rehmanniae polysaccharide	TAB Radix Rehmanniae polysaccharides, GSH, MDA, Tanshinone, Rhizoma, DNCB-induced, DNCB	B- DISEASE, CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL, DISEASE	E, D 185, 280, 334, 439, 626, 780	, 896, 217, 283, 337, 449, 633, 792, 90	3, 1045, 1070, 1084, 1239, 1276, 1547, 1808, 1827, 1861		
1377 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	x [TNF-q 90 d Trial: No AE Control: 12 AEs/Chellitis (3), pruritus and scale (7), Nausea with abdominal pain (2) Wang (2011) 60 Psoriasis vulgaris Randomized; Single center; Parallel 30 (17/13) 35.24 ± 10.28 y 30 (16/14) 33.48	TAB AEs/Cheilitis, pruritus, Nausea, abdominal pain, Psoriasis, Amino-polypeptide	DISEASE, DISEASE, DISEASE, DISEASE, DISEASE, CHEMICAL	36, 55, 79, 91, 129, 292	49, 63, 85, 105, 138, 309			
1383 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	xi TNF-a 4 w NR Han (2015) 80 Psoriatic pustules Randomized; Single center; Parallel 30 (17/13) 37.71 ± 12.8 y 30 (16/14) 36.48 ± 12.34 y Huayin Jiedu decoction (b.i.d) Acitretin (20 mg, b.i.d) 8.64 ± 5.43 y 8.51 ± 7.89 y 1.	TAB Acitretin	CHEMICAL		174 18	3		
1383 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	xl TNF-a NR NR Zhou (2016) 83 Psoriasis vulgaris Randomized; Single center; Parallel 82 (46/36) 35.7 ± 9.4 y 82 (48/34) 36.2 ± 9.7 y Shufeng jiedu capsules (12 caps, t.id) Compound amino-polypeptide tablets (6 tabs, b.i.c.	TAB Psoriasis	DISEASE		31 4			
1383 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	xl TNF-a 20 d Trial: No AE Control: No AE Du (2016b) 85 Psoriasis vulgaris Randomized; Single center; Parallel 24 (14/10) 41.75 ± 9.03 y 24 (15/9) 42.11 ± 10.95 y Heat-clearing and detoxicating oral liquid (60 mL, t.i.d) Acit	TAB Psoriasis, Heat-clearing, t.i.d, Acitretin, t.i.d	DISEASE, CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL	58, 167, 220, 227, 246	67, 180, 225, 236, 251			
1384 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	xi TNF-c 12 w NR Mao (2017) 86 Psoriasis vulgaris Randomized; Single center; Parallel 30 (21/9) 48.96 ± 6.88 y 30 (22/8) 48.02 ± 7.18 y 1.	TAB Psoriasis	DISEASE		33 4	2		
1385 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	xi TNF-a NR NR Yang (2018) 89 Psoriasis vulgaris Randomized; Single center; Parallel 35 (18/17) 33.89 ± 2.68 y 35 (17/18) 34.26 ± 2.91 y Jinji Xiaoyin granule (27 g, t.id) Acitretin (40 mg, b.id) 3.62 ± 3.21 y 3.26 ± 3.42 y t.	TAB Psoriasis, t.i.d, Acitretin	DISEASE, CHEMICAL, CHEMICAL	31, 170, 177	40, 175, 186			
1385 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/11_table-wrap/3_table	x, IL-23 5.TNF-a 8 w NR Wang (2019) 90 Psoriasis vulgaris Randomized; Single center; Parallel 36 (20/16) 41.4 ± 3.5 y 36 (18/18) 39.2 ± 2.4 y Qingying decoction (300 mL, b.i.d) Acitretin (20 mg, b.i.d) 15.1 ± 3.5 y 14.2 ± 27	TAB Psoriasis, Acitretin	DISEASE, CHEMICAL	40, 181	49, 190			
1387 /Users/emanuelfarruda/venv/phytomed100/PMC9230602/sections/4_floats-group/14_table-wrap/3_table	x, intervention and Comparator Intervention Outcomes Number of Participants (Studies) Anticipated Absolute Effects (95% CI) Quality of the Evidence (GRADE) EAHM compared to CM for inflammatory skin manifestation of pla	TAB CM, psoriasis, SMD 1.3204 SD lower (3.0143 lower	DISEASE, DISEASE, DISEASE	170, 219, 621	172, 228, 654	lower, lo	193, 162, 114, 136	, 194, 163, 115, 137
1394 /Users/emanuelfarruda/venv/phytomed100/PMC7703918/sections/1_body/2_3_results/4_3.4_identificat	io Number Compound Predicted Targets R.t (min) Area % 1 1-Pentanone, 1-Phenyl Akr1b1, ALOX15, Alox5, CHRM1, PPARA, PPARG, PLA2G1B, ESR1, Sqle 6.2809 0.5338 2 Benzenepropanoic acid AKR1B1, ALOX15, ALOX5	TAB Alox15, Butyric acid, Alox15, bis Ester, Nonanoic acid, Alox15, Tetradecanoic acid, Alox15, 1H	I-I CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL, CHEM	IICA 513, 768, 964, 1058, 1101, 1	129, 1 519, 780, 970, 1067, 1114, 1135,	1224, 1245, 1341, 1515, 1713, 1734, 1830, 2152, 2271, 2292, 2862, 2876, 2932, 2953, 3035, 3061		
1404 /Users/emanuelfarruda/venv/phytomed100/PMC9146286/sections/4_floats-group/11_table-wrap/3_table	x 35 Diosgenin and Glycyrrhiza glabra extract-loaded NLCs Dioscorea deltoidea Glycyrrhiza glabra Possessed lessened anti-inflammatory properties Inhibition of pro-inflammatory cytokines, TNF-q, IL, and enhanced ant	TAB Diosgenin, NLCs Dioscorea deltoidea, CA-loaded	CHEMICAL, CHEMICAL, CHEMICAL	7, 57, 393	16, 83, 402			
1462 /Users/emanuelfarruda/venv/phytomed100/PMC9626985/sections/2 bodv/4 5 pharmacological effects	o Oxidative stress-induced apportosis was reduced - Animal experiment : serum urea 1. uric acid 1. Scr 1. total protein (TP) 1. albumin (Alb) 1. albuse reductase (AR) 1. sorbitol dehydrocenase (ID)1. HbA1c 1. urinary olycosyla	TAB urea, uric acid, sorbitol, carboxymethyl lysine, sorbitol, IL-1b	CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL, CHEM	IICA 75. 83. 167. 244. 281. 322	79, 92, 175, 264, 289, 327	TP. Alb. AB total protein, albumin, aldose reductase	23, 29, 36	24, 30, 37
1463 /Users/emanuelfarruda/venv/obvtomed100/PMC9626985/sections/2 bodv/4 5 pharmacological effects	a Scavencing free radicals and anti-oxidation. Animal experiment : 1 TNF-o: II -18 and TGF-R1 levels in the serum and sciatic nerve of diabetic rats: regulation of oxidative-nitrosation stress in diabetic rats. 1 neuropathic pain	TAB TGE-61 diabetic diabetic peuropathic pain	CHEMICAL DISEASE DISEASE DISEASE	85 133 194 211	91 141 202 227			
1464 // lears/amanuelfarruda/venv/nbvtomed100/PMC9826985/sections/2_bodv/4_5_pharmacological_affacts	a Antiovidat activity in liver anti-userular ovidative stress. Animal experiment I ImRNA expression of II 18 II6. TNE-n and monorular chemostrad-art routein-1 (MCP-1) Learner resistin levels. Learner total cholesterol ar			210 301	221 312	MCP-1 monocyte chemoattractant protein-1	2	7 28
1527 /J sers/emanuelfarruida/venv/nbvtomed100/PMC9218575/sections/2_body/3_meta-analysis_of_curcumin	(72) Chronic inflammation, disease including MS and cardinates substantiate review and materials within 19 RCTs CRD horm. II. All and TNF-s that similar and a disease substantiate review and materials and substantiates and the substantiates a	TAB cardiovascular diseases	DISEASE	210,001	55 7			
1500 / Leare (amanuelfara ida/sonv/obutamed100/DMC0219575/cactions/2_body/2_meta_analysis_of_curcumin	(12) or the method of the second s			292 267	290.275			-
152 / Lears (amanuelfara da venu/phytomed 100/PMC9518/00/cactions/2_body/2_media analysis_o_candamini	1/10 minimized in the second s			42 190	51 198		-	-
1547 / Learn (american data verily phytomed 100/1 MC0007100 (sections 2_000/) 2_results 45_table-wrap 2_table	2222 Final control to control the standard method in the resolution of the standard of the standard method. Standard method is the standard method in the standard method is the standard method.	TAD siteste		43, 100	41 4			
/osers/emanuemanuemanuemanuemanuemanuemanuemanu	In Anti-manimatury Decreases the evolution induced and the expression and protein evens on manimation-related enzymes, indo and cover, and pointinamitationy optimizes, intro- in the evolution of the evolution o			00.00.404.505.000.4040	41 4			+
1950 /Users/emanuelramuda/venv/phytomed100/PMC830/380/sections/3_tioats-group/4_table-wrap/3_table.	m mais ability of assignment of the second	TAB jaundice, CCI, Extract, pyrrolidine dirhidcarbamate, writning, diciotenac	DISEASE, CHEMICAL, CHEMICAL, CHEMICAL, DISEASE, CHEMICAL	105 052 090	34, 42, 471, 532, 841, 1023			
1961 / Users/emanueirarruda/venv/phytomed 100/PMC8911698/sections/4_noats-group/5_table-wrap/3_table.	m 13 4 p-stosterol Male atomo wistar rats in vivo Anti-mammatory activity in ngn tat det- and sucrose-induced type-2 disclosed rats, p-stosterol treatment normalese raised serum evels of proininammatory cytokines, such a	TAB sucrose-induced type-2 diabetic, tumour necrosis, intereukin-6	DISEASE, DISEASE, CHEMICAL	105, 253, 289	136, 268, 302	IL-6 Intereukin-6	49	50
1565 /Users/emanueltarruda/venv/phytomed100/PMC9118284/sections/2_body/0_introduction/37_table-wrap	(2) Alleviated the increased expression of superoxide, NO and TNE- at 1, 5, and, 10 pM 9 Mouse Heducing gallbladder cancer 15, 30, and 60 mg/kg 10 Culture of H122 cell Alleviated the iodoacetic acid (IAA)-induced toxicity in c	IAB superoxide, NO, gallbladder cancer, iodoacetic acid, toxicity, HOS, Brain injury, trauma, diabet	ter CHEMICAL, CHEMICAL, DISEASE, CHEMICAL, DISEASE, CHEMICAL	L, D 39, 51, 98, 177, 207, 270, 32	4, 344 49, 53, 116, 192, 215, 273, 336,	350, 428, 443, 491, 695, 939, 1039, 10/4, 1251, 1294, 1338, 1587		+
1595 /Users/emanuelfarruda/venv/phytomed100/PMC8579746/sections/2_body/2_review/3_polymeric_nanoth	er/Assessment methods Assessment items Outcomes Counting of bacterial colonies E. coli, P. aeruginosa, S. aureus, P. vulgaris, C. albicans, C. freundii, K. pneumonia, C. glabrata Nanotherapeutics significantly reduce	TAB aeruginosa, freundii, K. pneumonia, bacterial infection, ulceration, inflammation, Tumor necros	sis DISEASE, DISEASE, DISEASE, DISEASE, DISEASE, DISEASE, DISEA	SE, 102, 154, 164, 230, 593, 993	, 1163 112, 162, 176, 249, 603, 1005, 1	17 TGF-β, TGF-β, fac Transforming growth factor-β family, Transforming growth factor-β family, factor-β family (T	(171, 204, 195, 251,	,1 172, 205, 196, 252,
1631 /Users/emanuelfarruda/venv/phytomed100/PMC9045588/sections/2_sub-article/1_body/5_table-wrap/0_	ta Ex benth, found in uttarakhand himalayas 72–73 39 hvG8j5cR WCPNP0332 Bhakti. Chandekar 1339 Neuroprotective Herbs and Foods From Different Traditional Medicines and Diet 73–74 40 3SUun6II WCPNP0676 Sujogya	TAB ', ', Rheumatoid Arthritis, Arthritis, CAIA, Curcumin	DISEASE, DISEASE, DISEASE, DISEASE, DISEASE, CHEMICAL	771, 788, 801, 851, 862, 101	1 772, 789, 821, 860, 866, 1019	CAIA Collagen-Antibody-Induced Arthritis	130	131
1636 /Users/emanuelfarruda/venv/phytomed100/PMC9002489/sections/4_floats-group/10_table-wrap/3_table	xi of a-Bisabolol alone a-Bisabolol -diclofenac (5.1, 10.3, 20.6, and 41.2 mg/kg) Formalin (50 µL of 1%, s.c.) induced nociception Carrageenan (100 µL of a 1%, s.c.)-induced inflammation in rats 1 nociception 1 paw volume 1	TAB inflammation, hemorrhagic erosion, p.o Carrageenan, intraplantar, dextran, histamine, seroton	in DISEASE, DISEASE, CHEMICAL, CHEMICAL, CHEMICAL, CHEMICAL	L, C 171, 221, 286, 320, 345, 380	, 406, 183, 240, 301, 332, 352, 389, 41	5, 449, 506, 564, 818, 957		
1638 /Users/emanuelfarruda/venv/phytomed100/PMC9002489/sections/4_floats-group/8_table-wrap/3_table.	m Neuroprotective Compound Dose/Route/ Duration Model Major Mechanisms Reference a-Bisabolol 5, 25, and 250 µmol/L for 7 days Rotenone (500 µmol/L) induced neurotoxicity in Drosophila 1 mortality and motor defici	TAB Rotenone, neurotoxicity, mg/kg, rotenone, Rotenone, Parkinson's disease → neuronal loss, M	D/ CHEMICAL, DISEASE, CHEMICAL, CHEMICAL, CHEMICAL, DISEASI	E, C 125, 155, 276, 301, 322, 351	, 390, 133, 168, 281, 309, 330, 386, 39	3, 400, 533, 542, 691, 799, 934, 1075, 1107, 1285, 1424, 1500, 1518		
1638 /Users/emanuelfarruda/venv/phytomed100/PMC9002489/sections/4_floats-group/11_table-wrap/3_table	x Cardioprotective Effects Compound Dose/Route/ Duration Model Major Mechanisms Reference a-Bisabolol 25 mg/kg, i.p for 10 days isoproterenol (85 mg/kg, s.c. for 2 days) induced myocardial infarction in rats 1 LDH, 1 in	TAB Isoproterenol, myocardial infarction, infarct, Isoproterenol, myocardial infarction, LOOH, GSH,	C CHEMICAL, DISEASE, DISEASE, CHEMICAL, DISEASE, CHEMICAL,	CHI 127, 177, 216, 457, 507, 553	, 586, 140, 198, 223, 470, 528, 557, 58	9, 595, 640, 805, 863, 893, 899, 913		
1638 /Users/emanuelfarruda/venv/phytomed100/PMC9002489/sections/4_floats-group/14_table-wrap/3_table	x Dose/Route/ Duration Model Major Mechanisms Reference Cells treated with: 2.5, 5, 10 µM for 24 h Mice treated with 30 mg/kg/day p.o daily for 8 weeks AGEs (50µg/mL for 2 h) induced OA in chondrocytes and Destabilization	TAB OA, nitrite, p.o, inflammation, alveolar hemorrhage, inflammation, p.o Carrageenan, pleurisy, µ	Ig/ DISEASE, CHEMICAL, CHEMICAL, DISEASE, DISEASE, DISEASE, CH	HEN 181, 283, 436, 504, 642, 748	, 822, 183, 290, 439, 516, 661, 760, 83	7, 879, 942		
1641 /Users/emanuelfarruda/venv/phytomed100/PMC7646887/sections/3_floats-group/5_table-wrap/2_table.	m Gene Sequence (5'-43') Coltat F: GCTCCTCTTAGGGGCCCACT R: ATTGGGGACCCTTAGGCCAT Colta2 F: TCGTGCCTAGCAACATGCC R: TTTGTCAGAATACTGAGCAGCAAC TGF F: GGCCTCTTCTGCGATTCG R: GCAGC	TAB TCGTGCCTAGCAACATGCC, AGAAACGGGACAAACTTCGTC	DISEASE, CHEMICAL	86, 245	105, 266			
1645 /Users/emanuelfarruda/venv/phytomed100/PMC9505094/sections/4_floats-group/4_table-wrap/3_table.	or Likewise, the highest dose of Ind inhibited the expression of PGE2, NO, IL-1β, COX-2, iNOS and TNF-a.	TAB NO	CHEMICAL		68 7			
1645 /Users/emanuelfarruda/venv/phytomed100/PMC9505094/sections/4_floats-group/4_table-wrap/3_table.x	or FRC also reduced the expression of NO and TNF-o; however, there were no differences between pre and coincubation.	TAB NO	CHEMICAL		35 3	7		
1646 /Users/emanuelfarruda/venv/phytomed100/PMC9505094/sections/4_floats-group/4_table-wrap/3_table.	or Both IGR and the extract suppressed the expression of NO, COX-2, TNF-o; IL-6; especially, NO production was decreased in LPS-stimulated RAW 264.7 cells.	TAB NO, NO	CHEMICAL, CHEMICAL	54, 90	56, 92			
1659 /Users/emanuelfarruda/venv/phytomed100/PMC9505094/sections/4_floats-group/4_table-wrap/3_table.s	m On the other hand, FPPEE pretreatment decreased elevated levels of MPO, NO, COX-2, TNF-α, NF-κB, IL-10, and SOD.	TAB NO	CHEMICAL		72 7	4		
1683 /Users/emanuelfarruda/venv/phytomed100/PMC9658815/sections/2_body/5_6skin_anti-aging_natural_	p Plants/Products Effects Refs Alchemilla mollis In vitro (NHDF cells) inhibition of AP-1 activation, c-Jun, and c-Fos levels, and increase in NH2 pathway 36 Allium sativum In vitro (HaCaT cells) inhibition of UV-induced in	TAB HaCat, Catechin, Thymus vulgaris	DISEASE, CHEMICAL, DISEASE	591, 694, 1761	596, 702, 1776			
1698 /Users/emanuelfarruda/venv/phytomed100/PMC9004605/sections/2_body/3_herbal_plants_exhibiting_ar	tit Inactivating NF-xB through the suppression of the pro-inflammatory tumor necrosis factor (TNF)-alpha	TAB tumor necrosis	DISEASE		67 8	1		
1702 /Users/emanuelfarruda/venv/phytomed100/PMC8746501/sections/4_floats-group/11_table-wrap/3_table	x Polyphenols Protective Effects and Mechanisms Conditions Study Types Hydroxytyrosol Impeding compartment propagation In hominoid promyelocytic In vitro Tempting caspase-mediated compartment demise via stunning	TAB Hydroxytyrosol, Resveratrol, colon tumor, estrogen, K, breast cancer, Quercetin, Luteolin, tyros	sir CHEMICAL, CHEMICAL, DISEASE, CHEMICAL, CHEMICAL, DISEASI	E, C 69, 342, 435, 655, 689, 731,	957, 9 83, 353, 446, 663, 690, 744, 966	976, 999, 1035, 1058, 1097, 1129, 1141, 1152, 1162, 1266, 1372, 1383, 1395, 1471, 1488		